Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A
Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half‐life (T1/2) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. Aims To determine immunogenicity, phar...
Saved in:
| Published in | Haemophilia : the official journal of the World Federation of Hemophilia Vol. 23; no. 2; pp. 238 - 246 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.03.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Introduction
Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half‐life (T1/2) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy.
Aims
To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)‐ylated FVIII (BAX 855) based on full‐length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A.
Methods
PTPs <12 years without history of FVIII inhibitors received twice‐weekly infusions of 50 ± 10 IU kg−1 BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg−1 were allowed under predefined conditions. PK was evaluated after single infusions of 60 ± 5 IU kg−1.
Results
T1/2 and mean residence time were extended 1.3‐ to 1.5‐fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg−1 of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred.
Conclusion
Twice‐weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A. |
|---|---|
| AbstractList | Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T sub(1/2)) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. Aims To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A. Methods PTPs <12 years without history of FVIII inhibitors received twice-weekly infusions of 50 plus or minus 10 IU kg super(-1) BAX 855 for greater than or equal to 50 exposure days. Prophylactic dose increases to less than or equal to 80 IU kg super(-1) were allowed under predefined conditions. PK was evaluated after single infusions of 60 plus or minus 5 IU kg super(-1). Results T sub(1/2) and mean residence time were extended 1.3- to 1.5-fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg super(-1) of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred. Conclusion Twice-weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A. Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T ) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A. PTPs <12 years without history of FVIII inhibitors received twice-weekly infusions of 50 ± 10 IU kg BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg were allowed under predefined conditions. PK was evaluated after single infusions of 60 ± 5 IU kg . T and mean residence time were extended 1.3- to 1.5-fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred. Twice-weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A. Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T1/2 ) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy.INTRODUCTIONPrimary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T1/2 ) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy.To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A.AIMSTo determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A.PTPs <12 years without history of FVIII inhibitors received twice-weekly infusions of 50 ± 10 IU kg-1 BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg-1 were allowed under predefined conditions. PK was evaluated after single infusions of 60 ± 5 IU kg-1 .METHODSPTPs <12 years without history of FVIII inhibitors received twice-weekly infusions of 50 ± 10 IU kg-1 BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg-1 were allowed under predefined conditions. PK was evaluated after single infusions of 60 ± 5 IU kg-1 .T1/2 and mean residence time were extended 1.3- to 1.5-fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg-1 of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred.RESULTST1/2 and mean residence time were extended 1.3- to 1.5-fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg-1 of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred.Twice-weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A.CONCLUSIONTwice-weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A. Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T1/2) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. Aims To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)-ylated FVIII (BAX 855) based on full-length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A. Methods PTPs <12 years without history of FVIII inhibitors received twice-weekly infusions of 50 ± 10 IU kg-1 BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg-1 were allowed under predefined conditions. PK was evaluated after single infusions of 60 ± 5 IU kg-1. Results T1/2 and mean residence time were extended 1.3- to 1.5-fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg-1 of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred. Conclusion Twice-weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A. Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half‐life (T1/2) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. Aims To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life of prophylaxis with a polyethylene glycol (peg)‐ylated FVIII (BAX 855) based on full‐length recombinant FVIII (ADVATE) in paediatric previously treated patients (PTPs) with severe haemophilia A. Methods PTPs <12 years without history of FVIII inhibitors received twice‐weekly infusions of 50 ± 10 IU kg−1 BAX 855 for ≥50 exposure days. Prophylactic dose increases to ≤80 IU kg−1 were allowed under predefined conditions. PK was evaluated after single infusions of 60 ± 5 IU kg−1. Results T1/2 and mean residence time were extended 1.3‐ to 1.5‐fold compared to ADVATE (n = 31), depending on the analysis used. The point estimate for the mean annualized bleeding rate in 66 subjects receiving a median of 1.9 weekly infusions of 51.3 IU kg−1 of BAX 855 each was 3.04 (median 2.0); 1.10 (median 0) for joint and 1.16 (median 0) for spontaneous bleeds. Overall, 38% of subjects had zero bleeds. No bleeds were severe. Haemostatic efficacy was rated excellent or good for 90% of bleeds; 91% were treated with one or two infusions. In 8/14 subjects all target joints resolved. No subject developed FVIII inhibitors or persistent binding antibodies that affected safety or efficacy. No adverse reactions occurred. Conclusion Twice‐weekly prophylaxis with BAX 855 was safe and efficacious in paediatric PTPs with severe haemophilia A. |
| Author | Osman, D. Engl, W. Sharkhawy, M. Stasyshyn, O. Mullins, E. S. Liesner, R. Abbuehl, B. E. Alvarez‐Román, M. T. |
| Author_xml | – sequence: 1 givenname: E. S. surname: Mullins fullname: Mullins, E. S. organization: Cincinnati Children's Hospital Medical Center – sequence: 2 givenname: O. surname: Stasyshyn fullname: Stasyshyn, O. organization: SI Institute of Blood Pathology and Transfusion Medicine of NAMSU – sequence: 3 givenname: M. T. surname: Alvarez‐Román fullname: Alvarez‐Román, M. T. organization: Hospital Universitario La Paz – sequence: 4 givenname: D. surname: Osman fullname: Osman, D. organization: Hospital Tengku Ampuan Rahimah – sequence: 5 givenname: R. surname: Liesner fullname: Liesner, R. organization: Great Ormond Street Hospital for Children – sequence: 6 givenname: W. surname: Engl fullname: Engl, W. organization: Baxalta Innovations GmbH, now part of Shire – sequence: 7 givenname: M. surname: Sharkhawy fullname: Sharkhawy, M. organization: Baxalta Innovations GmbH, now part of Shire – sequence: 8 givenname: B. E. surname: Abbuehl fullname: Abbuehl, B. E. email: Brigitt.abbuehl@shire.com organization: Baxalta Innovations GmbH, now part of Shire |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27891721$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc9u1DAQxi1URP_AgRdAlriARFqPk9jJcVUtdKVKXICr5XXGjSvHWeyEdsWFR-AZeRK87PZSgYQvHlm_75sZf6fkKIwBCXkJ7Bzyueg1nkMJ0D4hJ1CKuuA1iKNdXUPRcBDH5DSlW8ag5Ew8I8dcNi1IDifk-_J-wtBhR3vt7a8fP72zSDd4s_V6wu4dtbP3u2cMN1NPI5pxWLugw0StNtMY6ZfVakVtLjZx3PRZdu8SdYGa3vkuYqB3LgsTfsOIuQkOmXLeabp4Tp5a7RO-ONxn5PP75afLq-L644fV5eK6MBWHtujytCavKQ1v1p3hHLpSMotcGgmsFFaYDqWsbWV5UzLJWd3WrLGtNGCr0pRn5M3eN0_4dcY0qcElg97rgOOcFDQNSCHqtvoPtKrKWtRcZPT1I_R2nGPIiyhoOasyyXaGrw7UvB6wU5voBh236iGBDFzsARPHlCJaZdykJzeGKWrnFTC1y1jln1N_Ms6Kt48UD6Z_Yw_ud87j9t-gulos94rfqHu13g |
| CitedBy_id | crossref_primary_10_1007_s40778_019_00165_y crossref_primary_10_1055_s_0042_1756188 crossref_primary_10_1177_20406207231218624 crossref_primary_10_3390_jcm6040039 crossref_primary_10_1182_blood_2020005673 crossref_primary_10_1111_hae_13807 crossref_primary_10_2174_1389201024666230522091958 crossref_primary_10_1080_14728214_2021_1988073 crossref_primary_10_1080_13543784_2020_1723547 crossref_primary_10_1111_jth_14469 crossref_primary_10_1177_2040620718796429 crossref_primary_10_1111_jth_15036 crossref_primary_10_1056_NEJMoa2312611 crossref_primary_10_1080_21678707_2017_1334551 crossref_primary_10_1111_jth_15395 crossref_primary_10_1182_bloodadvances_2023011780 crossref_primary_10_1016_j_jtha_2023_03_011 crossref_primary_10_1055_s_0043_1778103 crossref_primary_10_1016_j_critrevonc_2022_103678 crossref_primary_10_1111_hae_14052 crossref_primary_10_1111_hae_14294 crossref_primary_10_1097_HS9_0000000000000144 crossref_primary_10_1111_hae_13963 crossref_primary_10_1016_j_thromres_2019_12_012 crossref_primary_10_1177_2040620717746312 crossref_primary_10_1111_hae_13403 crossref_primary_10_22209_IC_v62n1a07 crossref_primary_10_1080_14712598_2021_1908993 crossref_primary_10_1016_j_jtha_2023_07_030 crossref_primary_10_1039_D1NA00119A crossref_primary_10_3390_hematolrep15020039 crossref_primary_10_12688_f1000research_73884_1 crossref_primary_10_18553_jmcp_2020_26_4_492 crossref_primary_10_12688_f1000research_73884_2 crossref_primary_10_1080_17512433_2020_1776109 crossref_primary_10_1055_s_0040_1718887 crossref_primary_10_1002_rth2_12204 crossref_primary_10_12688_f1000research_73884_3 crossref_primary_10_1016_j_xphs_2023_05_014 crossref_primary_10_1111_hae_13905 crossref_primary_10_1186_s12929_021_00760_4 crossref_primary_10_1016_j_hoc_2019_01_007 crossref_primary_10_1080_17474086_2018_1564032 crossref_primary_10_1016_j_transci_2018_07_012 crossref_primary_10_1016_j_ijbiomac_2018_06_084 crossref_primary_10_1177_0192623319852300 crossref_primary_10_1111_hae_14048 crossref_primary_10_1177_20406207231178596 crossref_primary_10_1055_a_1665_6232 crossref_primary_10_1007_s00277_019_03747_2 crossref_primary_10_1182_blood_2018_08_872291 crossref_primary_10_1080_14656566_2021_1961742 crossref_primary_10_1111_ejh_14167 crossref_primary_10_1111_hae_13624 crossref_primary_10_21682_2311_1267_2021_8_4_103_104 crossref_primary_10_1182_bloodadvances_2022007529 crossref_primary_10_1080_17474086_2022_2112171 crossref_primary_10_1080_17474086_2023_2247160 crossref_primary_10_1111_hae_13980 crossref_primary_10_1111_hae_13862 crossref_primary_10_1007_s41669_021_00283_6 |
| Cites_doi | 10.1155/2015/596164 10.1056/NEJMe078098 10.1002/pst.449 10.1111/hae.12159 10.1055/s-0038-1656030 10.1111/j.1538-7836.2008.03032.x 10.1111/j.1365-2796.1994.tb00815.x 10.1111/jth.12911 10.1046/j.1365-2796.1997.130135000.x 10.1111/j.1538-7836.2010.03757.x 10.1111/j.1365-2516.2007.01536.x 10.1046/j.1365-2516.2002.00581.x 10.1111/j.1538-7836.2011.04611.x 10.1056/NEJMoa067659 10.1097/00005650-200108000-00006 10.1016/S0140-6736(11)61139-2 10.1182/blood-2013-10-529974 10.1160/TH06-02-0125 10.1182/blood-2015-03-630897 10.1111/j.1365-2516.2006.01268.x 10.1046/j.1365-2516.9.s1.4.x 10.1111/j.1365-2516.2004.00932.x 10.1111/hae.12165 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2 10.1002/sim.4386 10.1046/j.1365-2516.2002.00695.x 10.1016/0304-3959(83)90088-X |
| ContentType | Journal Article |
| Copyright | 2016 Baxalta Innovations GmbH. Published by John Wiley & Sons Ltd. 2016 Baxalta Innovations GmbH. Haemophilia Published by John Wiley & Sons Ltd. 2017 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2016 Baxalta Innovations GmbH. Published by John Wiley & Sons Ltd. – notice: 2016 Baxalta Innovations GmbH. Haemophilia Published by John Wiley & Sons Ltd. – notice: 2017 John Wiley & Sons Ltd |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 8FD FR3 H94 K9. P64 RC3 7X8 |
| DOI | 10.1111/hae.13119 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic Genetics Abstracts |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2516 |
| EndPage | 246 |
| ExternalDocumentID | 27891721 10_1111_hae_13119 HAE13119 |
| Genre | article Multicenter Study Journal Article |
| GrantInformation_xml | – fundername: Baxalta US Inc. |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 24P 29I 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EBX EGARE EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7T5 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 H94 K9. P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c4219-d278c1117c28bdc221d370fe27c71036f6cde775f4f283072059508f97c1f43c3 |
| IEDL.DBID | DR2 |
| ISSN | 1351-8216 1365-2516 |
| IngestDate | Fri Jul 11 11:24:23 EDT 2025 Fri Jul 11 00:58:32 EDT 2025 Fri Jul 25 09:49:32 EDT 2025 Wed Feb 19 01:57:15 EST 2025 Tue Jul 01 03:34:14 EDT 2025 Thu Apr 24 23:08:51 EDT 2025 Wed Jan 22 16:20:20 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | children prophylaxis extended half-life FVIII |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs http://creativecommons.org/licenses/by-nc-nd/4.0 2016 Baxalta Innovations GmbH. Haemophilia Published by John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4219-d278c1117c28bdc221d370fe27c71036f6cde775f4f283072059508f97c1f43c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhae.13119 |
| PMID | 27891721 |
| PQID | 1920484404 |
| PQPubID | 2045152 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1881766594 proquest_miscellaneous_1844356526 proquest_journals_1920484404 pubmed_primary_27891721 crossref_citationtrail_10_1111_hae_13119 crossref_primary_10_1111_hae_13119 wiley_primary_10_1111_hae_13119_HAE13119 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2017 2017-03-00 2017-Mar 20170301 |
| PublicationDateYYYYMMDD | 2017-03-01 |
| PublicationDate_xml | – month: 03 year: 2017 text: March 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Chichester |
| PublicationTitle | Haemophilia : the official journal of the World Federation of Hemophilia |
| PublicationTitleAlternate | Haemophilia |
| PublicationYear | 2017 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 13 2006; 96 1994; 236 2006; 12 2015; 126 2002; 8 2009 2011; 10 2008; 6 1983; 16 2007; 13 2012; 10 2012; 32 2012; 31 2013; 19 2004; 10 2007; 357 1997; 77 1997; 241 2003; 9 2015; 2015 2003; 3 2001; 39 2012; 379 1985; 10 2014; 123 2010; 8 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_31_1 e_1_2_10_30_1 Turecek PL (e_1_2_10_18_1) 2012; 32 Committee for Medicinal Products for Human Use (e_1_2_10_27_1) 2009 e_1_2_10_29_1 Godin G (e_1_2_10_25_1) 1985; 10 e_1_2_10_28_1 e_1_2_10_26_1 |
| References_xml | – volume: 77 start-page: 660 year: 1997 end-page: 7 article-title: A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A publication-title: Thromb Haemost – volume: 16 start-page: 87 year: 1983 end-page: 101 article-title: Assessment of chronic pain. I. Aspects of reliability and validity of the visual analogue scale publication-title: Pain – year: 2009 – volume: 10 start-page: 284 year: 2011 end-page: 8 article-title: Estimation of pharmacokinetic parameters publication-title: Pharm Stat – volume: 123 start-page: 317 year: 2014 end-page: 25 article-title: Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A publication-title: Blood – volume: 236 start-page: 391 year: 1994 end-page: 9 article-title: A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs. The Orthopaedic Outcome Study Group publication-title: J Intern Med – volume: 10 start-page: 359 year: 2012 end-page: 67 article-title: A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management publication-title: J Thromb Haemost – volume: 32 start-page: S29 issue: Suppl 1 year: 2012 end-page: 38 article-title: BAX 855, a PEGylated rFVIII product with prolonged half‐life. Development, functional and structural characterisation publication-title: Hamostaseologie – volume: 10 start-page: 141 year: 1985 end-page: 6 article-title: A simple method to assess exercise behavior in the community publication-title: Can J Appl Sport Sci – volume: 357 start-page: 603 year: 2007 end-page: 5 article-title: Prophylactic treatment for prevention of joint disease in hemophilia–cost versus benefit publication-title: N Engl J Med – volume: 9 start-page: 101 issue: Suppl 1 year: 2003 end-page: 10 article-title: Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective publication-title: Haemophilia – volume: 379 start-page: 1447 year: 2012 end-page: 56 article-title: Modern haemophilia care publication-title: Lancet – volume: 357 start-page: 535 year: 2007 end-page: 44 article-title: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia publication-title: N Engl J Med – volume: 96 start-page: 433 year: 2006 end-page: 40 article-title: Evidence for the benefits of prophylaxis in the management of hemophilia A publication-title: Thromb Haemost – volume: 8 start-page: 745 year: 2002 end-page: 52 article-title: Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome publication-title: Haemophilia – volume: 31 start-page: 1059 year: 2012 end-page: 73 article-title: Non‐compartmental estimation of pharmacokinetic parameters for flexible sampling designs publication-title: Stat Med – volume: 126 start-page: 1078 year: 2015 end-page: 85 article-title: Pegylated, full‐length, recombinant factor VIII for prophylactic and on‐demand treatment of severe hemophilia A publication-title: Blood – volume: 3 start-page: 329 year: 2003 end-page: 41 article-title: The PedsQL as a pediatric population health measure: feasibility, reliability and validity publication-title: Ambul Pediatr – volume: 19 start-page: 698 year: 2013 end-page: 705 article-title: Results from a large multinational clinical trial (guardianTM3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics publication-title: Haemophilia – volume: 2015 start-page: 596164 year: 2015 article-title: Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on‐demand publication-title: ScientificWorldJournal – volume: 39 start-page: 800 year: 2001 end-page: 12 article-title: PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory Version 4.0 generic core scales in healthy and patient populations publication-title: Med Care – volume: 10 start-page: 428 year: 2004 end-page: 37 article-title: Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A publication-title: Haemophilia – volume: 12 start-page: 117 issue: Suppl 3 year: 2006 end-page: 21 article-title: Pathogenesis of haemophilic arthropathy publication-title: Haemophilia – volume: 241 start-page: 395 year: 1997 end-page: 400 article-title: Haemophilia prophylaxis in young patients ‐ a long‐term follow‐up publication-title: J Intern Med – volume: 19 start-page: 691 year: 2013 end-page: 7 article-title: Results from a large multinational clinical trial (guardianTM1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy publication-title: Haemophilia – volume: 13 start-page: 20 issue: Suppl 3 year: 2007 end-page: 5 article-title: Prevention of haemophilic synovitis: prophylaxis publication-title: Haemophilia – volume: 6 start-page: 1319 year: 2008 end-page: 26 article-title: Plasma and albumin free recombinant factor VIII (rAHF‐PFM): pharmacokinetics, efficacy and safety in previously treated pediatric patients publication-title: J Thromb Haemost – volume: 13 start-page: 967 year: 2015 end-page: 77 article-title: Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A publication-title: J Thromb Haemost – volume: 8 start-page: 44 year: 2002 end-page: 50 article-title: Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients publication-title: Haemophilia – volume: 8 start-page: 730 year: 2010 end-page: 6 article-title: Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring publication-title: J Thromb Haemost – ident: e_1_2_10_14_1 doi: 10.1155/2015/596164 – ident: e_1_2_10_5_1 – volume: 10 start-page: 141 year: 1985 ident: e_1_2_10_25_1 article-title: A simple method to assess exercise behavior in the community publication-title: Can J Appl Sport Sci – ident: e_1_2_10_8_1 doi: 10.1056/NEJMe078098 – ident: e_1_2_10_28_1 doi: 10.1002/pst.449 – ident: e_1_2_10_32_1 doi: 10.1111/hae.12159 – ident: e_1_2_10_16_1 doi: 10.1055/s-0038-1656030 – ident: e_1_2_10_20_1 doi: 10.1111/j.1538-7836.2008.03032.x – ident: e_1_2_10_9_1 doi: 10.1111/j.1365-2796.1994.tb00815.x – ident: e_1_2_10_33_1 doi: 10.1111/jth.12911 – ident: e_1_2_10_6_1 doi: 10.1046/j.1365-2796.1997.130135000.x – ident: e_1_2_10_21_1 doi: 10.1111/j.1538-7836.2010.03757.x – volume: 32 start-page: S29 issue: 1 year: 2012 ident: e_1_2_10_18_1 article-title: BAX 855, a PEGylated rFVIII product with prolonged half‐life. Development, functional and structural characterisation publication-title: Hamostaseologie – ident: e_1_2_10_13_1 doi: 10.1111/j.1365-2516.2007.01536.x – ident: e_1_2_10_11_1 doi: 10.1046/j.1365-2516.2002.00581.x – ident: e_1_2_10_15_1 doi: 10.1111/j.1538-7836.2011.04611.x – ident: e_1_2_10_7_1 doi: 10.1056/NEJMoa067659 – ident: e_1_2_10_23_1 doi: 10.1097/00005650-200108000-00006 – ident: e_1_2_10_2_1 doi: 10.1016/S0140-6736(11)61139-2 – ident: e_1_2_10_34_1 doi: 10.1182/blood-2013-10-529974 – ident: e_1_2_10_12_1 doi: 10.1160/TH06-02-0125 – ident: e_1_2_10_19_1 doi: 10.1182/blood-2015-03-630897 – volume-title: Guideline on the Clinical Investigation of Recombinant and Human Plasma‐Derived Factor VIII Products year: 2009 ident: e_1_2_10_27_1 – ident: e_1_2_10_3_1 doi: 10.1111/j.1365-2516.2006.01268.x – ident: e_1_2_10_26_1 – ident: e_1_2_10_17_1 doi: 10.1046/j.1365-2516.9.s1.4.x – ident: e_1_2_10_31_1 doi: 10.1111/j.1365-2516.2004.00932.x – ident: e_1_2_10_30_1 doi: 10.1111/hae.12165 – ident: e_1_2_10_22_1 doi: 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2 – ident: e_1_2_10_4_1 – ident: e_1_2_10_29_1 doi: 10.1002/sim.4386 – ident: e_1_2_10_10_1 doi: 10.1046/j.1365-2516.2002.00695.x – ident: e_1_2_10_24_1 doi: 10.1016/0304-3959(83)90088-X |
| SSID | ssj0013206 |
| Score | 2.4201295 |
| Snippet | Introduction
Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended... Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T... Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended... Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 238 |
| SubjectTerms | Antibodies Bleeding Child Child, Preschool Children Coagulation factors extended half‐life FVIII Factor VIII - therapeutic use Factor VIII deficiency Female Hemophilia Hemophilia A - drug therapy Hemophilia A - pathology Humans Immunogenicity Male Pharmacokinetics Polyethylene glycol Prophylaxis Prospective Studies Quality of Life Side effects |
| Title | Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhae.13119 https://www.ncbi.nlm.nih.gov/pubmed/27891721 https://www.proquest.com/docview/1920484404 https://www.proquest.com/docview/1844356526 https://www.proquest.com/docview/1881766594 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIiEuvCkL7cogDhzIauNkY0ectmVXu0gghCjqASly_OhGpGnV3ZV4XPgJ_Y39Jcw4D7W8hLhEUTJJ7Njj-TwefwPwdGhipaQxwTC15K3Cg3TKBDLSaExw1myUD5B9k8z241cHo4MNeNHuhan5ITqHG2mGH69JwVW-vKDkC2UHxBVDm_coVosA0Tt-YQXB59WkBHSB5GHSsApRFE_35GVb9AvAvIxXvcGZ3oSPbVHrOJNPg_UqH-ivP7E4_mddbsGNBoiycd1zbsOGre7AtdfNUvtd-DZp3ONsoUp3_v2sLJxlJ_bwS4nw1Dxn5Liny7Y6XC0YTayPch9Ww-ocPuzDfD5niIkZVgEbs1SfiyUrKtbuH2fkA2Zome2pxY_YI5QqykKx8T3Yn07e782CJlNDoGMc8gLDhdRYFaG5zI3mPDSRGDrLhUYEEyUu0cYKMXKxI8IxwRHUITJ0qdChiyMd3YfN6riyD4DlyVCk2pk8knHMVZTqkQwdDsmIjLQOdQ-etW2W6YbGnLJplFk7ncECZ_5n9uBJJ3pSc3f8Tmi7bfisUd9lhrAXRzaiTuzB4-42Kh6tpqjKHq9RBu9HCId58jcZSQScoxTfs1V3qq4ktAWZ5t9YId81_lzEbDae-JOH_y76CK5zAiA-Wm4bNlena7uD8GmV9-EKj9_24ep49-XutO-15gdW6xix |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VIgEX3o9AgQWBxAFH8dqx1wcOEU0V08cBtag3s95HY-G6VZMIChd-Aj-Ev8Kf4Jcws36o5SUuPXCJonhi765ndr6dnf0G4MlAh1IKrb1BYihahR_CSu2JQKEzwVWzli5Bdiua7ISvdoe7S_C1PQtT80N0ATeyDDdfk4FTQPqElU-l6RNZTNKkVK6b4_e4YJu9SFfx7T7lfG28_XLiNTUFPBWicXqax0Lh_2PFRa4V574O4oE1PFboa4PIRkqbOB7a0BI1VswRfiCGsUmsfBsGKsD7noPzVEGcmPpXX_MTexaukieVvPME96OGx4jyhrqmnvZ-v0Da0wjZubi1K_CtHZw6s-VdfzHP--rjT7yR_8voXYXLDdZmo9o4rsGSqa7Dhc0mm-AGfBo3OwBsKkv7_fOXsrCGHZq94xIRuH7OqDP0s6n25lNGsYP93GUOsbpMEXuTpilD2M9wzFBfS_mhmLGiYu0ReUZhbobgwxwZfIjZR6miLCQb3YSdM-n6LViuDipzB1geDeJEWZ0HIgy5DBI1FL5Fr4PgTylf9eBZqySZapjaqWBImbUrNmxw5l5eDx53ooc1PcnvhFZaTcuaGWqWIbLHyZvYIXvwqLuMcwttGMnKHCxQBq8HiPh59DcZQRyjwwTvc7vW4q4ldMqaQgzYIaeLf25iNhmN3Ze7_y76EC5Otjc3so10a_0eXOKEt1xy4Aosz48W5j6ixXn-wBkpg7dnrdc_AKWucXE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG8WChgEEgdSbZxs7Bw4rOiuNhSqHijqLTh-dCOl6aq7FVRc-An8D_4Vv4QZ56FWPMSllyhKJsnE9ni-GY9nAJ4PTayUNCYYppa8VXiQTplARhqVCVrNRvkA2d1kth-_PRgdrMGPbi9Mkx-id7iRZPj5mgR8Ydw5IZ8ru0W5YtI2onLHnn1Ge235OtvGzn3B-XTy4c0saEsKBDpG2QwMF1Lj80JzWRjNeWgiMXSWC42qNkpcoo0VYuRiR5mxBEf0gRDGpUKHLo50hO-9AldpcZHix3i8d27JwhfypIp3geRh0qYxorChntWLyu83RHsRIHsNN70B11toysbNWLoJa7a-BRvv28X32_B10jrM2VxV7ue371XpLFvYw7MKAat5xciVT5dtfbiaMzK1jwofaMOaqj7sY5ZlDFEyQ56weyv1pVyysmbdjnJGXmGGutqeWPyIPUKqsioVG9-B_Utp6LuwXh_X9j6wIhmKVDtTRDKOuYpSPZKhw0kasZLWoR7Ay65Rc90mNqf6GlXeGTjIcO7bfwDPetJFk83jT0SbXc_krUAvcwTCONdRMsUBPO1voyjS-oqq7fEp0uD9CAEyT_5FIykl5yjF99xrer3nhDYlk0WOP-SHwd9ZzGfjiT958P-kT2Bjb3uav8t2dx7CNU7oxIfSbcL66uTUPkJstSoe-zHN4NNlC9Evxpww9A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Extended+half%E2%80%90life+pegylated%2C+full%E2%80%90length+recombinant+factor+VIII+for+prophylaxis+in+children+with+severe+haemophilia+A&rft.jtitle=Haemophilia+%3A+the+official+journal+of+the+World+Federation+of+Hemophilia&rft.au=Mullins%2C+E.+S.&rft.au=Stasyshyn%2C+O.&rft.au=Alvarez%E2%80%90Rom%C3%A1n%2C+M.+T.&rft.au=Osman%2C+D.&rft.date=2017-03-01&rft.issn=1351-8216&rft.eissn=1365-2516&rft.volume=23&rft.issue=2&rft.spage=238&rft.epage=246&rft_id=info:doi/10.1111%2Fhae.13119&rft.externalDBID=10.1111%252Fhae.13119&rft.externalDocID=HAE13119 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-8216&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-8216&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-8216&client=summon |